Singapore BIOPHARMA PTE. LTD. announces that VisuECTOINE® has received market approval from Singapore's Health Sciences Authority (HSA).
VisuECTOINE® is the TRIPLE ACTION drop for ocular irritation and allergy.
Singapore BIOPHARMA PTE. LTD. announces exclusive distribution rights for StroVac® suspension for injection in Singapore.
StroVac® is an advanced bacterial lysate therapy designed for the prevention and treatment of recurrent urinary tract infections (rUTIs). It offers a non-antibiotic prevention approach, with clinically validated efficacy and up to a 95% recurrence-free rate.
Singapore BIOPHARMA PTE. LTD. announces exclusive distribution rights for VisuEVO® in Singapore.
VisuEVO® is a multifunction eye drop designed for patients with evaporative dry eye disease.
Singapore BIOPHARMA PTE. LTD. officially announces the acquisition of exclusive distribution rights for Ferabright® in Singapore.
FEABRIGHT is the first and only FDA-approved iron-based contrast agent for brain MRI in adults with known or suspected intracranial malignant tumors, helping visualize lesions with a disrupted blood-brain barrier.
Singapore BIOPHARMA PTE. LTD. announces exclusive distribution rights for RYANODEX® (dantrolene sodium) for injectable in Singapore.
RYANODEX® is an injectable formulation indicated for the rapid treatment of malignant hyperthermia (MH).
Singapore BIOPHARMA PTE. LTD. announces exclusive distribution rights for Feraheme® (ferumoxytol injection) in Singapore.
Feraheme® is an intravenous iron formulation.
Singapore BIOPHARMA PTE. LTD. officially announces the acquisition of exclusive distribution rights for BARHEMSYS® (amisulpride) injection in Singapore.
BARHEMSYS® is an intravenous amisulpride injection specifically designed for timely and aggressive treatment of breakthrough postoperative nausea and vomiting (PONV) in patients. This product provides perioperative healthcare professionals with an effective PONV management solution.
Singapore BIOPHARMA PTE. LTD. officially announces the acquisition of exclusive distribution rights for Macrilen® (Macimorelin) in Singapore.
Macrilen® is an oral growth hormone secretagogue receptor agonist specifically designed for the diagnosis of Adult Growth Hormone Deficiency (AGHD). This product provides clinicians with a convenient and accurate diagnostic tool.
For more information, please contact:
Singapore BIOPHARMA PTE. LTD.
Email: info@biopharma.com.sg
Tel: +65 8279 4183